These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20167258)

  • 1. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.
    Xu K; Xu YH; Chen JF; Schwarzschild MA
    Neuroscience; 2010 May; 167(2):475-81. PubMed ID: 20167258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.
    Xu K; Xu YH; Chen JF; Schwarzschild MA
    Neurosci Lett; 2002 Mar; 322(1):13-6. PubMed ID: 11958832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
    Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
    Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effect of naringenin against MPTP-induced oxidative stress.
    Sugumar M; Sevanan M; Sekar S
    Int J Neurosci; 2019 Jun; 129(6):534-539. PubMed ID: 30433834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
    Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
    Boireau A; Dubedat P; Bordier F; Imperato A; Moussaoui S
    Neuropharmacology; 2000 Apr; 39(6):1016-20. PubMed ID: 10727711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
    Saitoh T
    J Neurol Sci; 1988 Feb; 83(2-3):161-6. PubMed ID: 3258627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection.
    Singh S; Singh K; Patel DK; Singh C; Nath C; Singh VK; Singh RK; Singh MP
    Rejuvenation Res; 2009 Jun; 12(3):185-97. PubMed ID: 19594327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
    Grünblatt E; Mandel S; Maor G; Youdim MB
    J Neurochem; 2001 Apr; 77(1):146-56. PubMed ID: 11279270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
    Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
    Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
    Li C; Biswas S; Li X; Dutta AK; Le W
    J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.
    Ding H; Underwood R; Lavalley N; Yacoubian TA
    Neuroscience; 2015 Oct; 307():73-82. PubMed ID: 26314634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
    Feng G; Zhang Z; Bao Q; Zhang Z; Zhou L; Jiang J; Li S
    Biol Pharm Bull; 2014; 37(8):1301-7. PubMed ID: 24871044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
    Fujita A; Fujita Y; Pu Y; Chang L; Hashimoto K
    Psychopharmacology (Berl); 2020 Jan; 237(1):83-92. PubMed ID: 31418048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
    Chen JF; Xu K; Petzer JP; Staal R; Xu YH; Beilstein M; Sonsalla PK; Castagnoli K; Castagnoli N; Schwarzschild MA
    J Neurosci; 2001 May; 21(10):RC143. PubMed ID: 11319241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
    Kurkowska-Jastrzebska I; Litwin T; Joniec I; Ciesielska A; Przybyłkowski A; Członkowski A; Członkowska A
    Int Immunopharmacol; 2004 Oct; 4(10-11):1307-18. PubMed ID: 15313429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-allyl cysteine protects against MPTP-induced striatal and nigral oxidative neurotoxicity in mice: participation of Nrf2.
    García E; Santana-Martínez R; Silva-Islas CA; Colín-González AL; Galván-Arzate S; Heras Y; Maldonado PD; Sotelo J; Santamaría A
    Free Radic Res; 2014 Feb; 48(2):159-67. PubMed ID: 24147739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.